Listening: Novartis criticises new US drug pricing rules
On Thursday, Novartis reiterated its claim that the US pricing of its Entresto drug was “unconstitutional”. Prices set under the White House’s Inflation Reduction Act (IRA) will limit access to medicine, the Basel firm says.
This content was published on
2 minutes
Keystone-SDA
Français
fr
Novartis critique les nouveaux prix fixés aux USA pour Entresto
Original
The price-setting process is “not objective or transparent” and does not reflect the true value of a drug, Novartis wrote in a press releaseExternal link. For the Basel-based pharmaceutical giant, the new prices set under US President Joe Biden’s IRA will also have “long-lasting and devastating consequences for patients by limiting access to medicines now and in the future”.
Currently, US patients pay an average of $29 (CHF25.24) a month for Entresto, a drug to treat heart failure. The IRA, a wide-ranging program of energy transition and social reform, plans to lower the prices of ten drugs for treating serious illnesses – including Entresto – after January 2026.
Under pressure, and despite strong reluctance, several major pharmaceutical companies, including Novartis, agreed to take part in negotiations with Medicare, the health insurance scheme for the over-65s in the United States.
“We acceded to a “maximum fair price” for Entresto for 2026 only to avoid other untenable options including catastrophic fines or the removal of all our products from both Medicare and Medicaid,” Novartis said in its press release.
Adapted from French by DeepL/dos
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Controversial Russian soprano Anna Netrebko returns to Zurich
This content was published on
Russian soprano Anna Netrebko, who is said to be close to Russian president Vladimir Putin, to perform at the Zurich Opera House.
This content was published on
Multiple births following artificial insemination in Switzerland have fallen sharply over the last 20 years, shrinking from 17.4% in 2002 to 2.8% in 2023.
This content was published on
Three independent UN experts call on Switzerland and other countries to redouble efforts a year after a ECHR ruling in favour of Climate Elders.
“No US tariff negotiations”: Swiss economics minister
This content was published on
Switzerland has yet to enter formal tariff negotiations with the United States despite making contact with the administration.
Soaring cocoa prices hit Swiss chocolate maker Barry Callebaut
This content was published on
Swiss chocolate maker Barry Callebaut suffered from soaring cocoa prices in the first half of the 2024-2025 financial year.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.